GlassScriptPhysician profile
Susan Peck
NPI 1588643233
$2,950.21
in general payments reported to CMS, 2019-2025
22 companies · $497 in 2025
The $497 reported for 2025 was more than what 87% of Addiction Medicine (Preventive Medicine) providers received nationally (typical 2025 total: $115).
See the full distribution for Addiction Medicine (Preventive Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $378 · 2021: $881 · 2022: $283 · 2023: $382 · 2024: $249 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.40 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $711.96 | 2021-2023 | Zimhi, Lucemyra |
| Abbvie INC. | $534.33 | 2019-2025 | |
| Indivior INC. | $433.62 | 2019-2025 | Sublocade |
| Braeburn INC. | $182.74 | 2023-2025 | Brixadi |
| Mdd US Operations, LLC | $177.88 | 2020 | |
| Gilead Sciences, INC. | $141.64 | 2023-2024 | |
| Alkermes, INC. | $129.56 | 2019-2024 | Vivitrol, Vivitrol |
| Vertex Pharmaceuticals Incorporated | $97.71 | 2025 | |
| Biogen, INC. | $88.73 | 2022 | |
| Neurocrine Biosciences, INC. | $71.03 | 2023-2025 | Ingrezza |
| Hologic Sales and Service, LLC | $65.90 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.00 | 2020-2022 | |
| Axonics, INC. | $58.33 | 2021 | |
| Mayne Pharma Commercial LLC | $35.25 | 2021-2023 | |
| Coloplast Corp | $29.68 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $27.64 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $20.79 | 2020 | |
| Astellas Pharma US INC | $18.92 | 2019 | |
| Avion Pharmaceuticals | $17.70 | 2022 | |
| Evofem Biosciences, INC. | $17.43 | 2021 | |
| Duchesnay USA Incorporated | $16.13 | 2020 | |
| Pfizer INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Peck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.